Catalyst
Monitor enrollment rates, interim results, and safety data as the trial progresses over the next 7-8 months.
Date
July 4, 2026
Phase
N/A
Status
watch
Signal score
8.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.